Compare RMBI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RMBI | SGMT |
|---|---|---|
| Founded | 1887 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.6M | 169.4M |
| IPO Year | 2019 | 2021 |
| Metric | RMBI | SGMT |
|---|---|---|
| Price | $15.24 | $7.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 39.9K | ★ 2.6M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.77 | $3.15 |
| 52 Week High | $16.04 | $11.41 |
| Indicator | RMBI | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 64.03 | 63.02 |
| Support Level | $13.07 | $6.61 |
| Resistance Level | N/A | $7.86 |
| Average True Range (ATR) | 0.40 | 0.71 |
| MACD | 0.08 | 0.17 |
| Stochastic Oscillator | 64.92 | 60.08 |
Richmond Mutual Bancorp Inc is a bank holding company. Along with its subsidiary, it is mainly engaged in attracting deposits from the general public, as well as brokered deposits, and investing those funds in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one- to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. It also obtains funds by utilizing Federal Home Loan Bank (FHLB) advances. These funds are generally invested in investment securities, including mortgage-backed and mortgage-related securities and agency and municipal bonds. The Group's primary market area includes Wayne and Shelby counties in Indiana and Shelby, Miami, and Franklin counties in Ohio.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.